VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

More documents

Recommendations

Info

CONTENTS nviAum TMLHTA'I OTT! 7 A l ) SESSION I: Leukemia - UK MRCIO: EVALUATION OF AUTO-BMT IN ACUTE MYELOID LEUKAEMIA .UJlJ 1 T i J / A.K.BURNETT, A.H.GOLDSTONE, R.F. STEVENS, L. HANN, J. REE§, R.GRAY AND K. WHEATLEY 1 - {Y h/ ' ALLOGENEIC VERSUS AUTOLOGOUS BONE MARROW TRANSPLANTATION (BMT) VERSUS INTENSIVE CONSOLIDATION IN ACUTE MYELOGENOUS LEUKEMIA (AML) IN FIRST REMISSION. AN EORTC-GIMEMA PHASE III TRIAL (AML 8 A ) " m A PRELIMINARY ANALYSIS 6 R. ZITTOUN 1 , F. MANDELLI. R. WILLEMZE, T. DE WITTE, S. IURA, P.R. FERRINI, P. STRYCKMANS, F. UMLAUF, M. DARDENNE, M.C. PETTI, G. SOLBU, M.L. VEGNA, S. SUCIU RANDOMIZED TRIAL COMPARING AUTOLOGOUS STEM CELL TRANSPLANTATION AND CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST REMISSION: THE BGMT GROUP EXPERIENCE 11 J. REIFFERS, A.M. STOPPA, M. ATTAL, M. MICHALLET, G. MARITl, D. BLAISE F. HUGUET, B. CORRONT P. CONY-MAKHOUL, M. MONTASTRUC, J.A. GASTAUT, G. LAURENT, L. MOLINA, A. BROUSTET. D. MARANINCHI, J. PRIS, D. HOLLARD, C FABERES COMPARISON OF INTENSIVE CONSOLIDATION CHEMOTHERAPY (ICC) AND UNPURGED AUTOLOGOUS BONE MARROW TRANSPLANTATION (ABMT) AS POST REMISSION THERAPY IN ADULT ACUTE MYELOID LEUKEMIA (AML) 16 JL HAROUSSEAU*, JY CAHN, B PIGNON, D MIGNARD, F WITZ, C LIN ASSIER, NIFRAH, B LIOURE, D CAILLOT, F GUILHOT, JF ABGRALL, PY LEPRISE, D GUYOTAT, P CASASSUS, J BRIERE, F MORS, B DESABLENS, P HURTELOUP SESSION II: Future Directions IMPROVED OUTCOME FOR HIGH-RISK AML USING AUTOLOGOUS BONE MARROW TRANSPLANTATION AND MONOCLONAL ANTIBODY PURGED BONE MARROW 21 K. J. SELVAGGI, J. WILSON, L. E. MILLS, G. G. CORNWELL III, D. HURD, R. GINGRICH, E. MARTIN, W. MILLER AND E. D. BALL SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION
Page 1: Autologous Bone Marrow Transplantat
Page 6 and 7: ENHANCED REGENERATION OF NATURAL KI
Page 8 and 9: THE PHARMACOLOGY OF INTENSIVE CYCLO
Page 10 and 11: AUTOLOGOUS PHILADELPHIA (PH) CHROMO
Page 13: Preface The Sixth International Sym
Page 17 and 18: UK MRCIO: EVALUATION OF AUTO-BMT IN
Page 19 and 20: sible in an environment where acces
Page 21 and 22: Matched Donor Figure 2 Progress to
Page 23 and 24: included in the ABMT/intensive chem
Page 25 and 26: EORTC and the GIMEMA groups, despit
Page 27 and 28: RANDOMIZED TRIAL COMPARING AUTOLOGO
Page 29 and 30: RESULTS From January 1987 to Decemb
Page 31 and 32: BQtIT 87 Diaaasa Fraa Survival "ASC
Page 33 and 34: or ZRB 200 mg/m 2 /d d5-6. After he
Page 35: 5. HAROUSSEAU JL, MILPIED N, BRIERE
Page 39 and 40: IMPROVED OUTCOME FOR HIGH-RISK AML
Page 41 and 42: TOXICITY Preparation Regimen The pr
Page 43 and 44: DISCUSSION BMT after high-dose chem
Page 45 and 46: 0.1 - ABMT with mAb purging for AML
Page 47 and 48: MATERIALS AND METHODS Patients. Fif
Page 49 and 50: cells and their precursors that are
Page 51 and 52: CYCLOSPORINE-INDUCED GRAFT-VERSUS-H
Page 53 and 54: after ABMT; 8 had positive skin bio
Page 55 and 56:
tion of differentiation-associated
Page 57 and 58:
T lymphocytes seem to be particular
Page 59 and 60:
Gale, New York, Wiley-Liss, 1990. 3
Page 61 and 62:
5 30 CD56 positive NK cells On Off
Page 63 and 64:
THE USE OF GRANULOCYTE COLONY-STIMU
Page 65:
Table 1. G-CSF in ABMT: Patient Cha
Page 69 and 70:
PERIPHERAL BLOOD STEM CELL TRANSPLA
Page 71 and 72:
plant; two others died of intercurr
Page 73 and 74:
Table 1: Cox Model Parameters 1983
Page 75:
Table 5: Patient's quality of life
Page 79 and 80:
AUTOLOGOUS BONE MARROW TRANSPLANTAT
Page 81 and 82:
cal remission, 28 patients had no r
Page 83 and 84:
o PRIOR CR 1 1 1 1 , 1 0 20 40 60 8
Page 85 and 86:
ized in table 1. There were 21 male
Page 87 and 88:
significant difference was observed
Page 89 and 90:
TABLE 1. PATIENT CHARACTERISTICS No
Page 91 and 92:
Figure 1 ^ years SIXTH INTERNATIONA
Page 93 and 94:
Page 95 and 96:
Figure 2 Low grade lymphoma - progr
Page 97 and 98:
Page 99 and 100:
RESULTS AND TOXICITY In all cases t
Page 101 and 102:
Med 104:757-765,1986. 11. Velasquez
Page 103 and 104:
Table 2. Histology According to the
Page 105:
Session V: Hodgkin's
Page 108 and 109:
HIGH-DOSE THERAPY AND ABMT IN FIRST
Page 110 and 111:
HODGKIN'S DISEASE: AUTOLOGOUS BMT F
Page 112 and 113:
"unstimulated" 11 peripheral blood
Page 114 and 115:
PROGRESSIVE HODGKIN'S DISEASE MARRO
Page 116 and 117:
MARROW TRANSPLANTATION AFTER MARROW
Page 118 and 119:
(Table 2). Patients receiving ThioT
Page 120 and 121:
TABLE 2. PATIENT CHARACTERISTICS #
Page 122 and 123:
RADIOIMMUNOTHERAPY FOR BONE MARROW
Page 124 and 125:
PATIENT SELECTION RIT is in a devel
Page 126 and 127:
6. Klein JL, Nguyen TH, Laroque P,
Page 128 and 129:
HIGH DOSE INTERCALATOR BASED THERAP
Page 130 and 131:
throughout their hospital stay and
Page 132 and 133:
cytosine arabinoside in refractory
Page 134 and 135:
Table 1. Patient Characteristics No
Page 137 and 138:
RESULTS WITH CONVENTIONAL DOSE CHEM
Page 139 and 140:
ined modality therapy that included
Page 141 and 142:
X * G à E i s ¡8 1 ¡1 if o 2 3 k
Page 143 and 144:
3 C/5 < < < < O < I Z2ZZ N 2 ^J^ini
Page 145 and 146:
Intensive hydration to maintain hig
Page 147 and 148:
10. Spitzer G, Farha P, Valdivieso
Page 149 and 150:
47 94 142 189 Weeks 236 283 Figure
Page 151 and 152:
agents are given intermittently in
Page 153 and 154:
PD CORRELATES OF PK MEASUREMENTS. B
Page 155:
Evening Session
Page 158 and 159:
CD34 antibodies are removed by glyc
Page 160 and 161:
glycoprotein half-life, etc) of the
Page 162 and 163:
SELECTION OF PH-NEGATIVE PROGENITOR
Page 164 and 165:
culture, CFU-GM growth was signific
Page 166 and 167:
TRANSDUCTION AND EXPRESSION OF THE
Page 168 and 169:
and were infected five times over a
Page 170 and 171:
DNA from human nucleated cells. Nuc
Page 172 and 173:
O 600 Fig. 3A: Transduction of CD34
Page 174 and 175:
AUTOLOGOUS STEM CELL HARVEST AND EV
Page 176 and 177:
tration of 5% DMSO, 4% albumin and
Page 178 and 179:
Table 3. Prognostic factors in pred
Page 181:
Session VII: Testicular
Page 184 and 185:
completion of conventional salvage
Page 186 and 187:
treatment of poor risk non seminoma
Page 188 and 189:
TOXICITY Mean time to PMN count >50
Page 190 and 191:
TABLE 1: PATIENTS' CHARACTERISTICS
Page 193 and 194:
INTENSIVE COMBINED MODALITY THERAPY
Page 195 and 196:
chest and upper abdominal computeri
Page 197 and 198:
nosed by fine needle aspirate, pres
Page 199 and 200:
Soc, Series A. 1972; 135:185-198. 8
Page 201 and 202:
Induction Chemotherapy to Maximum R
Page 203 and 204:
Table 1: Characteristics of 30 Pati
Page 205 and 206:
Table 3: SITES OF RELAPSE N Relapse
Page 207 and 208:
marrow support with or without peri
Page 209 and 210:
Table 4. Resulte of VP-16/Platlnol
Page 211 and 212:
HIGH DOSE RADIOTHERAPY FOR NON-SMAL
Page 213:
mens that incorporate biological pr
Page 217 and 218:
CONVENTIONAL TREATMENT RESULTS IN E
Page 219 and 220:
suits of treatment remain unsatisfa
Page 221 and 222:
platelet support. This drug combina
Page 223 and 224:
Table 1. Operative Staging of Ovari
Page 225 and 226:
Table 3. Response Complete response
Page 227 and 228:
Higher dose carboplatin with marrow
Page 229 and 230:
leukemia, Hodgkin's and non-Hodgkin
Page 231:
transplantation for refractory soli
Page 235 and 236:
HIGH DOSE CHEMOTHERAPY AND AUTOLOGO
Page 237 and 238:
graphies are given in Table 1. In a
Page 239 and 240:
VP-16 CBDCA CYTOXAN DAY SCHEMA FOR
Page 241:
Session XI: CML
Page 244 and 245:
Busulfan (4mg/kg/day 4 days) and hi
Page 246 and 247:
6. Reiffers J, Trouette R, Marit G,
Page 248 and 249:
RESULTS Hematological recovery to >
Page 250 and 251:
AUTOLOGOUS PHILADELPHIA (PH) CHROMO
Page 252 and 253:
stage. However, the clinical result
Page 255 and 256:
HIGH DOSE NITROSUREA FOLLOWED BY AB
Page 257 and 258:
Lung complications were observed 22
Page 259 and 260:
eceived 800mg/m 2 . 7 patients rece
Page 261:
Table 1: Extrahematological toxicit
Page 265 and 266:
INFLUENCE OF MINIMAL TUMOR CONTAMIN
Page 267 and 268:
patients. Not surprisingly the PSCT
Page 269 and 270:
THE RECOMBINANT HUMAN LIGAND FOR C-
Page 271 and 272:
a significant increase in the numbe
Page 273 and 274:
15. Molineux G, Pojda Z, et al: A c
Page 275 and 276:
It was the objective of our study t
Page 277 and 278:
Interestingly, patients autografted
Page 279 and 280:
CR/PR Relapse 1—1 Chemotherapy Tr
Page 281 and 282:
EFFECTS OF TWO SCHEDULES OF ADMINIS
Page 283 and 284:
cells because of the bad haematolog
Page 285 and 286:
sion in this arm. The evolution of
Page 287 and 288:
Table 2. PBSC harvest. arm A arm 6
Page 289:
Summaries
Page 292 and 293:
R. Harousseau reviewed the results
Page 294 and 295:
- as far as relapses are concerned:
Page 296 and 297:
PHASE III STUDIES There are a very
Page 298 and 299:
INDICATIONS FOR AUTOLOGOUS BONE MAR
Page 300 and 301:
ies of ASCT in first complete remis
Page 302 and 303:
Karel A. Dicke, Arlington Cancer Ce
Page 304 and 305:
Chris Poynton, Department of Hemato
show all

VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

Create successful ePaper yourself

Delete template?

Save as template?